News & Updates

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

01 Jul 2025 by

The APHINITY trial of adding pertuzumab to adjuvant therapy for early HER2+ breast cancer turns in a significant OS improvement, with results presented at ESMO Breast Cancer 2025 concluding a phase III trial spanning over a decade

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

01 Jul 2025

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Treatment of immune checkpoint inhibitors (ICIs) has led to a more than twofold increase in survival for patients with advanced Merkel cell carcinoma (MCC) at the population level, translating to about 220 fewer deaths annually in the US, according to a study.

ICIs improve survival in advanced MCC at population level

30 Jun 2025

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025 by

The oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI) zongertinib confers clinically meaningful benefit to patients with previously treated HER2-mutant nonsmall cell lung cancer (NSCLC), including those with brain metastases, while having a manageable safety profile, according to the phase 1A/1B Beamion LUNG-1 trial.

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

28 Jun 2025 by

For women with gynaecologic cancer undergoing inpatient palliative care in Singapore, music therapy helps create a comfortable space to disengage from difficult realities, celebrate life, and process grief and other challenging emotions, as shown in a qualitative study.

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

28 Jun 2025

TDABC may improve resource use in cancer care

27 Jun 2025 by

A study done in a single institution in Singapore has demonstrated the feasibility and practical application of time-driven activity-based costing (TDABC) in measuring the financial burden of chemotherapy regimens within an ambulatory oncology setting.

TDABC may improve resource use in cancer care

27 Jun 2025

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

27 Jun 2025 by

Despite positive outcomes with the KEYNOTE-522 regimen for triple-negative breast cancer (TNBC), its implementation faces challenges due to resource constraints in Hong Kong’s public healthcare system. Consultant Dr Thomas Kwan-Hang Lau and Resident Dr Kang Li of the Department of Clinical Oncology at Prince of Wales Hospital (PWH) shared insights and a case series on the use of Q3W and Q1W chemotherapy for the KEYNOTE-522 regimen in PWH and explored alternative neoadjuvant chemotherapy options.

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

27 Jun 2025

Is anal cancer screening in MSM with HIV worth the buck?

26 Jun 2025

Screening for anal cancer among men who have sex with men (MSM) with HIV aged ≥35 years is cost-effective, according to a recent study. However, there is a need for value-based prioritization strategies to improve screening use.

Is anal cancer screening in MSM with HIV worth the buck?

26 Jun 2025

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025 by

The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

26 Jun 2025 by

Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, shares key insights from TITAN and OASIS studies and highlights the association between PSA response and survival outcomes.

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

26 Jun 2025

Review underpins poor functional outcomes in AYAs with bony sarcomas

25 Jun 2025 by

In a scoping review examining the functional outcomes of individuals with bony sarcomas, adolescent and young adult oncology (AYAO) patients seem to fare worse than their healthy counterparts and bony sarcoma patients from various age groups.

Review underpins poor functional outcomes in AYAs with bony sarcomas

25 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

Adjuvant pertuzumab delivers survival gain in HER2+ EBC

ICIs improve survival in advanced MCC at population level

ICIs improve survival in advanced MCC at population level

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

Music therapy provides valuable support in gynaecologic cancer patients in palliative care in SG

TDABC may improve resource use in cancer care

TDABC may improve resource use in cancer care

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

Is anal cancer screening in MSM with HIV worth the buck?

Is anal cancer screening in MSM with HIV worth the buck?

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Diabetes in CHD patients ups risk of hepatocellular carcinoma

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

Review underpins poor functional outcomes in AYAs with bony sarcomas

Review underpins poor functional outcomes in AYAs with bony sarcomas